FIELD: chemistry.
SUBSTANCE: invention relates to indazole derivatives having a structure of the formula I, or to its pharmaceutically acceptable salts, in which R1 and R2 have the meaning given in the claims. Methods for treating Wnt-related disease states are also described.
.
EFFECT: claimed indazole derivatives may find use in the treatment of disorders characterized by activation of the Wnt-signaling pathway (for example, cancer, abnormal cell proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), when modulating cellular events mediated by Wnt-signaling, as well as treating genetic diseases and neurological conditions, disorders or diseases mediated by mutation or disregulation of the Wnt pathway and/or one or more components of Wnt signaling.
34 cl, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDASOLE INHIBITORS OF Wnt SIGNAL PATH AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2638932C2 |
| INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/β-CATENIN SIGNAL INHIBITORS | 2012 |
|
RU2627693C2 |
| 1H-PYRAZOLO[3,4-B]PYRIDINES AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2689141C2 |
| METHODS FOR USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF WNT/B-CATENIN SIGNAL PATH | 2017 |
|
RU2770613C2 |
| NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
| PYRAZOLE DERIVATIVE SUITABLE AS PI3K INHIBITOR | 2016 |
|
RU2710549C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
